Myit Mahar Trading Co., Ltd. Pharmaceutical Import Profile — Myanmar (DGFT 2022–2026)

Name: Myit Mahar Trading Co., Ltd. Pharmaceutical Import Records from India — 2 Products, $2.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Myit Mahar Trading Co., Ltd. — Pharmaceutical Importer Profile (2026) | 2 Products, $2.8M Trade | TransData Nexus

Myit Mahar Trading Co., Ltd.

Pharmaceutical Importer · Myanmar · Cardiovascular Focus · $2.8M Total Trade · DGFT Verified

Myit Mahar Trading Co., Ltd. is a pharmaceutical importer based in Myanmar with a total trade value of $2.8M across 2 products in 2 therapeutic categories. Based on 61 verified import shipments from Indian Customs (DGFT) records, Myit Mahar Trading Co., Ltd. is the #1 buyer in 1 product including Bambuterol. Myit Mahar Trading Co., Ltd. sources from 6 verified Indian suppliers, with Sun Pharmaceutical Industries Limited accounting for 97.2% of imports.

Myit Mahar Trading Co., Ltd. — Import Portfolio & Supplier Network

Myit Mahar Trading Co., Ltd. import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Myit Mahar Trading Co., Ltd.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$23.7M	949	97.2%
Lupin Limited	$424.9K	12	1.7%
Inventia Healthcare Limited	$122.7K

What Formulations Does Myit Mahar Trading Co., Ltd. Import?

Formulation	Value	Ships
Amlosun 5 tablets ( amlodipine tablets	$700.0K	14
Amlosun 10 tablets (amlodipine tablets	$400.7K	9
Maxgalin 50 capsules (pregabalin	$314.5K	9
Zeptol 200 tablets(carbamazepine	$313.8K	8
Aztor TAB 10 MG Each film coated	$273.3K	6
Levipil 500 tablets (levetiracetam	$262.5K	11
Nexito 5 tablets (escitalopram oxalate	$258.8K	8
Cardivas 3.125MG tablets (carvedilol TAB	$250.0K	5
Etoshine 90 tabs(etoricoxib tablets 90	$246.6K	8
Dicorate er 250 tablets (divalproex	$237.7K	7
Cardivas 6.25MG tablets (carvedilol	$200.0K	4
Cardivas 3.125MG tablets Pack : 03*10	$200.0K	4
Aztor TAB 10 MG Pack : box5x10s batch :pte4112a Each film coated tablet contains atorvastatin calcium eq. to	$199.6K	4
Montek TAB 10MG Each tablets contains	$190.8K	4
Pantocid dsr capsules( enteric coated	$188.6K	6

Myit Mahar Trading Co., Ltd. imports 582 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Amlodipine	Cardiovascular	$2.7M	54	0.0%	11
2	Bambuterol	Respiratory & OTC	$99.8K	7	43.9%	1

Myit Mahar Trading Co., Ltd. imports 2 pharmaceutical products across 2 categories into Myanmar totaling $2.8M. The company is the #1 buyer for 1 product: Bambuterol.

Myit Mahar Trading Co., Ltd. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Myit Mahar Trading Co., Ltd. is a pharmaceutical importer and distributor based in Yangon, Myanmar. Established to meet the growing demand for quality healthcare products, the company plays a pivotal role in Myanmar's pharmaceutical supply chain by sourcing and distributing a diverse range of finished pharmaceutical formulations. Its operations are primarily focused on importing medications from India, which are then distributed across Myanmar to various healthcare providers, including hospitals, clinics, and pharmacies.

The company's headquarters are located at No. 93, 2nd Floor, Lu Nge Thitsar Street, 12 Quarter, Yankin Township, Yangon Region, Myanmar. This strategic location facilitates efficient logistics and distribution within the country. While specific information about a parent company is not readily available, Myit Mahar Trading Co., Ltd. operates as an independent entity, dedicated to enhancing the accessibility of essential pharmaceutical products throughout Myanmar.

2Distribution Network

Myit Mahar Trading Co., Ltd. maintains a centralized distribution model with its primary warehouse situated in Yangon. This centralization enables the company to effectively manage inventory and streamline the distribution process to various regions within Myanmar. The company's logistics capabilities are tailored to meet the demands of the domestic market, ensuring timely delivery of pharmaceutical products to healthcare facilities nationwide. While there is no publicly available information regarding expansion beyond Myanmar, the company's current focus remains on serving the domestic market.

3Industry Role

In Myanmar's pharmaceutical supply chain, Myit Mahar Trading Co., Ltd. functions as a primary wholesaler and distributor. By importing finished pharmaceutical formulations from India, the company bridges the gap between international manufacturers and local healthcare providers. This role is crucial in ensuring the availability of a wide range of medications, thereby supporting the healthcare infrastructure across Myanmar. The company's operations are integral to the efficient functioning of the pharmaceutical distribution network within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Myit Mahar Trading Co., Ltd.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Myit Mahar Trading Co., Ltd. exhibits a high degree of supplier concentration, with a significant portion of its imports sourced from a limited number of suppliers. Notably, Sun Pharmaceutical Industries Ltd. accounts for a substantial majority of the company's imports, indicating a strong reliance on this supplier. This concentration suggests that the company has established a strategic partnership with Sun Pharmaceutical Industries Ltd., potentially benefiting from favorable terms and consistent product quality.

However, such dependency also presents risks, including potential supply chain disruptions if issues arise with the primary supplier. The company's limited diversification in sourcing could impact its ability to mitigate risks associated with supplier-related challenges. To enhance supply chain resilience, it would be prudent for Myit Mahar Trading Co., Ltd. to consider diversifying its supplier base, thereby reducing dependency on a single source and ensuring a more robust supply chain.

2Supply Chain Resilience

The resilience of Myit Mahar Trading Co., Ltd.'s supply chain is closely tied to its relationship with Sun Pharmaceutical Industries Ltd., which constitutes a significant portion of its imports. While this strong partnership may offer benefits such as consistent product quality and favorable terms, it also exposes the company to risks associated with over-reliance on a single supplier. The company's limited diversification in sourcing could pose challenges in the event of supply chain disruptions or changes in supplier dynamics.

Importing Pharmaceuticals into Myanmar — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Myanmar

1Regulatory Authority & Framework

In Myanmar, the regulation of pharmaceutical products is governed by the Ministry of Health and Sports, which oversees the registration, importation, and distribution of drugs. The National Drug Law, enacted in 1992, provides the legal framework for the control and regulation of pharmaceutical products within the country. This law outlines the procedures for drug registration, licensing, quality assurance, labeling, and advertising, ensuring that pharmaceutical products meet the required standards for safety, efficacy, and quality. (servicetrade.gov.mm)

The National Drug Law mandates that all pharmaceutical products must be registered with the Drug Regulatory Authority before they can be imported, distributed, or sold in Myanmar. This registration process involves the submission of detailed product information, including composition, manufacturing processes, and clinical data, to demonstrate the product's safety and efficacy. Additionally, the law stipulates that all pharmaceutical products must comply with the labeling requirements set forth by the Ministry of Health and Sports, ensuring that consumers receive accurate and comprehensive information about the products they use. (servicetrade.gov.mm)

2Import Licensing & GMP

Import licensing in Myanmar is governed by the National Drug Law, which requires all entities involved in the importation, storage, distribution, or sale of pharmaceutical products to obtain the necessary licenses from the Ministry of Health and Sports. This includes import licenses, wholesale distribution authorizations, and Good Manufacturing Practice (GMP) certificates. The GMP certification ensures that pharmaceutical products are manufactured in facilities that adhere to internationally recognized quality standards, thereby guaranteeing the safety and efficacy of the products. (servicetrade.gov.mm)

Myit Mahar Trading Co., Ltd. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Myit Mahar Trading Co., Ltd. focuses its product strategy on importing pharmaceutical formulations that address prevalent health concerns in Myanmar, particularly in the cardiovascular and respiratory therapeutic areas. The company's import data indicates a significant emphasis on cardiovascular medications, such as Amlodipine, and respiratory treatments like Bambuterol. This strategic focus aligns with the high incidence of cardiovascular diseases and respiratory conditions in the country, reflecting the company's commitment to meeting the critical healthcare needs of the Myanmar population.

The decision to import these specific therapeutic categories is driven by market demand and the availability of effective treatments from Indian manufacturers. By concentrating on these areas, Myit Mahar Trading Co., Ltd. aims to provide essential medications that improve patient outcomes and support the overall health infrastructure in Myanmar. This targeted product strategy underscores the company's role in enhancing access to vital healthcare solutions within the country.

2Sourcing Profile

Myit Mahar Trading Co., Ltd. primarily sources generic pharmaceutical formulations from India, focusing on finished products rather than active pharmaceutical ingredients (APIs) or bulk drugs. This sourcing strategy allows the company to offer a wide range of medications that are both cost-effective

Frequently Asked Questions — Myit Mahar Trading Co., Ltd.

What products does Myit Mahar Trading Co., Ltd. import from India?

Myit Mahar Trading Co., Ltd. imports 2 pharmaceutical products across 2 categories. Top imports: Amlodipine ($2.7M), Bambuterol ($99.8K).

Who supplies pharmaceuticals to Myit Mahar Trading Co., Ltd. from India?

Myit Mahar Trading Co., Ltd. sources from 6 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (97.2% of imports, $23.7M).

What is Myit Mahar Trading Co., Ltd.'s total pharmaceutical import value?

Myit Mahar Trading Co., Ltd.'s total pharmaceutical import value from India is $2.8M, based on 61 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Myit Mahar Trading Co., Ltd. focus on?

Myit Mahar Trading Co., Ltd. imports across 2 categories. The largest: Cardiovascular (96.4%), Respiratory & OTC (3.6%).

Get Full Myit Mahar Trading Co., Ltd. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.